Id: acc1528
Group: 2sens_supp
Protein: ErbB3
Gene Symbol: ERBB3
Protein Id: P21860
Protein Name: ERBB3_HUMAN
PTM: ubiquitination
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype:
Disease Cellline: MCF7
Disease Info:
Drug: NRG1 OV
Drug Info: -
Effect: modulate
Effect Info: "Akt promotes the stability of the deubiquitinase USP8 by phosphorylating the T907 site of USP8, leading to the ubiquitination and degradation of ErbB3. The overexpression of ErbB3 is often associated with increased malignancy, metastasis, and enhanced chemoresistance of tumors."
Note: Non-conventional drugs
Score: 3.0
Pubmed(PMID): 17210635
Sentence Index:
Sentence:

Sequence & Structure:

MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATTTLGSALSLPVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMPRGCLASESSEGHVTGSEAELQEKVSMCRSRSRSRSPRPRGDSAYHSQRHSLLTPVTPLSPPGLEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEYMNRRRRHSPPHPPRPSSLEELGYEYMDVGSDLSASLGSTQSCPLHPVPIMPTAGTTPDEDYEYMNRQRDGGGPGGDYAAMGACPASEQGYEEMRAFQGPGHQAPHVHYARLKTLRSLEATDSAFDNPDYWHSRLFPKANAQRT

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - neoplasm ATC
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid carcinoma DailyMed
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid neoplasm EMA
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 Active, not recruiting thyroid cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - medullary thyroid gland carcinoma DailyMed
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ERBB3 PATRITUMAB Receptor tyrosine-protein kinase erbB-3 inhibitor 3 Terminated non-small cell lung carcinoma ClinicalTrials
ERBB3 POZIOTINIB Epidermal growth factor receptor inhibitor 3 Suspended non-small cell lung carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Active, not recruiting thyroid cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed thyroid cancer ClinicalTrials
ERBB3 PATRITUMAB Receptor tyrosine-protein kinase erbB-3 inhibitor 3 Terminated lung cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed lung cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Active, not recruiting medullary thyroid gland carcinoma ClinicalTrials
ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Withdrawn medullary thyroid gland carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Completed hepatocellular carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Completed head and neck squamous cell carcinoma ClinicalTrials
ERBB3 TARLOXOTINIB Epidermal growth factor receptor inhibitor 2 Terminated head and neck squamous cell carcinoma ClinicalTrials
ERBB3 CDX-3379 Receptor tyrosine-protein kinase erbB-3 inhibitor 2 Terminated head and neck squamous cell carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Unknown status acute myeloid leukemia ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Terminated clear cell renal carcinoma ClinicalTrials
ERBB3 SAPITINIB Receptor tyrosine-protein kinase erbB-3 inhibitor 2 Completed colorectal adenocarcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Completed glioblastoma multiforme ClinicalTrials
ERBB3 POZIOTINIB Epidermal growth factor receptor inhibitor 2 Terminated lung adenocarcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Terminated follicular thyroid carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Terminated mesothelioma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - P Breast cancer/tumor/carcinoma Phosphorylation 11389077
- - P Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 21246584
- - U Ovarian cancer/carcinoma Phosphorylation 22841590

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: